Loading
MARS 2 is the trial that overturned decades of surgical practice: removing the lining of the lung did not help patients live longer and left them worse off.
Survival was worse with surgery (HR 1.28, 95% CI 1.02-1.60; median 19.3 vs 24.8 months), with more serious adverse events and poorer quality of life. Extended pleurectomy/decortication is no longer recommended outside trials in most guidelines; MARS 1 had earlier cast doubt on extrapleural pneumonectomy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
335 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Surgery + chemotherapy | 169 | 19.3 months | 1.28 (1.02 to 1.6) | - | link |
| Chemotherapy alone | 166 | 24.8 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pleura, Pleural mesothelioma, Mesothelioma.
Shares Pleura, Pleural mesothelioma, Mesothelioma.
Shares Pleura, Mesothelioma.
Shares Extended pleurectomy/decortication & radical mesothelioma surgery, Mesothelioma.
Shares Dean A. Fennell, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/